Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry

the Blue Light Cystoscopy with Cysview Registry Group

doi:10.1111/bju.15614

Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry

the Blue Light Cystoscopy with Cysview Registry Group

Urology

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Objectives: To evaluate the role of blue-light cystoscopy (BLC) in detecting invasive tumours that were not visible on white-light cystoscopy (WLC). Patients and Methods: Using the multi-institutional Cysview registry database, patients who had at least one white-light negative (WL–)/blue-light positive (BL+) lesion with invasive pathology (≥T1) as highest stage tumour were identified. All WL–/BL+ lesions and all invasive tumours in the database were used as denominators. Relevant baseline and outcome data were collected. Results: Of the 3514 lesions (1257 unique patients), 818 (23.2%) lesions were WL−/BL+, of those, 55 (7%) lesions were invasive (48 T1, seven T2; 47 unique patients) including 28/55 (51%) de novo invasive lesions (26 unique patients). In all, 21/47 (45%) patients had WL−/BL+ concommitant carcinoma in situ and/or another T1 lesions. Of 22 patients with a WL−/BL+ lesion who underwent radical cystectomy (RC), high-risk pathological features leading to RC was only visible on BLC in 18 (82%) patients. At time of RC, 11/22 (50%) patients had pathological upstaging including four (18%) with node-positive disease. Conclusions: A considerable proportion of invasive lesions are only detectable by BLC and the rate of pathological upstaging is significant. Our present findings suggest an additional benefit of BLC in the detection of invasive bladder tumours that has implications for treatment approach.

Original language	English (US)
Pages (from-to)	62-67
Number of pages	6
Journal	BJU International
Volume	130
Issue number	1
DOIs	https://doi.org/10.1111/bju.15614
State	Published - Jul 2022

Bibliographical note

Funding Information:
Siamak Daneshmand is a paid consultant for Photocure. Yair Lotan is a paid consultant for Photocure and does research with Storz. Sima Porten is a paid consultant for Photocure. Brian Willard has research funding from and on speakers bureau for Photocure. Additional research funding with Jansseen, Myriad, and Coloplast. Gary D. Steinberg is a paid consultant for Photocure. Also, he is a member of Clinical Trial Protocol Committees for Photocure.

Publisher Copyright:
© 2021 The Authors BJU International © 2021 BJU International.

Keywords

bladder cancer
blue-light cystoscopy
cystoscopy
detection rate
diagnosis
invasive tumour

PubMed: MeSH publication types

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1111/bju.15614

OpenUrl availability

Full text

Cite this

@article{b9056f1450b34c149ab9f322a51f417f,

title = "Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry",

abstract = "Objectives: To evaluate the role of blue-light cystoscopy (BLC) in detecting invasive tumours that were not visible on white-light cystoscopy (WLC). Patients and Methods: Using the multi-institutional Cysview registry database, patients who had at least one white-light negative (WL–)/blue-light positive (BL+) lesion with invasive pathology (≥T1) as highest stage tumour were identified. All WL–/BL+ lesions and all invasive tumours in the database were used as denominators. Relevant baseline and outcome data were collected. Results: Of the 3514 lesions (1257 unique patients), 818 (23.2%) lesions were WL−/BL+, of those, 55 (7%) lesions were invasive (48 T1, seven T2; 47 unique patients) including 28/55 (51%) de novo invasive lesions (26 unique patients). In all, 21/47 (45%) patients had WL−/BL+ concommitant carcinoma in situ and/or another T1 lesions. Of 22 patients with a WL−/BL+ lesion who underwent radical cystectomy (RC), high-risk pathological features leading to RC was only visible on BLC in 18 (82%) patients. At time of RC, 11/22 (50%) patients had pathological upstaging including four (18%) with node-positive disease. Conclusions: A considerable proportion of invasive lesions are only detectable by BLC and the rate of pathological upstaging is significant. Our present findings suggest an additional benefit of BLC in the detection of invasive bladder tumours that has implications for treatment approach.",

keywords = "bladder cancer, blue-light cystoscopy, cystoscopy, detection rate, diagnosis, invasive tumour",

author = "{the Blue Light Cystoscopy with Cysview Registry Group} and Hamed Ahmadi and Ladi-Seyedian, {Seyedeh Sanam} and Badrinath Konety and Kamal Pohar and Holzbeierlein, {Jeffrey M.} and Max Kates and Brian Willard and Taylor, {Jennifer M.} and Liao, {Joseph C.} and Kaimakliotis, {Hristos Z.} and Porten, {Sima P.} and Steinberg, {Gary D.} and Tyson, {Mark D.} and Yair Lotan and Siamak Daneshmand",

note = "Funding Information: Siamak Daneshmand is a paid consultant for Photocure. Yair Lotan is a paid consultant for Photocure and does research with Storz. Sima Porten is a paid consultant for Photocure. Brian Willard has research funding from and on speakers bureau for Photocure. Additional research funding with Jansseen, Myriad, and Coloplast. Gary D. Steinberg is a paid consultant for Photocure. Also, he is a member of Clinical Trial Protocol Committees for Photocure. Publisher Copyright: {\textcopyright} 2021 The Authors BJU International {\textcopyright} 2021 BJU International.",

year = "2022",

month = jul,

doi = "10.1111/bju.15614",

language = "English (US)",

volume = "130",

pages = "62--67",

journal = "BJU International",

issn = "1464-4096",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Role of blue-light cystoscopy in detecting invasive bladder tumours

T2 - data from a multi-institutional registry

AU - the Blue Light Cystoscopy with Cysview Registry Group

AU - Ahmadi, Hamed

AU - Ladi-Seyedian, Seyedeh Sanam

AU - Konety, Badrinath

AU - Pohar, Kamal

AU - Holzbeierlein, Jeffrey M.

AU - Kates, Max

AU - Willard, Brian

AU - Taylor, Jennifer M.

AU - Liao, Joseph C.

AU - Kaimakliotis, Hristos Z.

AU - Porten, Sima P.

AU - Steinberg, Gary D.

AU - Tyson, Mark D.

AU - Lotan, Yair

AU - Daneshmand, Siamak

N1 - Funding Information: Siamak Daneshmand is a paid consultant for Photocure. Yair Lotan is a paid consultant for Photocure and does research with Storz. Sima Porten is a paid consultant for Photocure. Brian Willard has research funding from and on speakers bureau for Photocure. Additional research funding with Jansseen, Myriad, and Coloplast. Gary D. Steinberg is a paid consultant for Photocure. Also, he is a member of Clinical Trial Protocol Committees for Photocure. Publisher Copyright: © 2021 The Authors BJU International © 2021 BJU International.

PY - 2022/7

Y1 - 2022/7

N2 - Objectives: To evaluate the role of blue-light cystoscopy (BLC) in detecting invasive tumours that were not visible on white-light cystoscopy (WLC). Patients and Methods: Using the multi-institutional Cysview registry database, patients who had at least one white-light negative (WL–)/blue-light positive (BL+) lesion with invasive pathology (≥T1) as highest stage tumour were identified. All WL–/BL+ lesions and all invasive tumours in the database were used as denominators. Relevant baseline and outcome data were collected. Results: Of the 3514 lesions (1257 unique patients), 818 (23.2%) lesions were WL−/BL+, of those, 55 (7%) lesions were invasive (48 T1, seven T2; 47 unique patients) including 28/55 (51%) de novo invasive lesions (26 unique patients). In all, 21/47 (45%) patients had WL−/BL+ concommitant carcinoma in situ and/or another T1 lesions. Of 22 patients with a WL−/BL+ lesion who underwent radical cystectomy (RC), high-risk pathological features leading to RC was only visible on BLC in 18 (82%) patients. At time of RC, 11/22 (50%) patients had pathological upstaging including four (18%) with node-positive disease. Conclusions: A considerable proportion of invasive lesions are only detectable by BLC and the rate of pathological upstaging is significant. Our present findings suggest an additional benefit of BLC in the detection of invasive bladder tumours that has implications for treatment approach.

AB - Objectives: To evaluate the role of blue-light cystoscopy (BLC) in detecting invasive tumours that were not visible on white-light cystoscopy (WLC). Patients and Methods: Using the multi-institutional Cysview registry database, patients who had at least one white-light negative (WL–)/blue-light positive (BL+) lesion with invasive pathology (≥T1) as highest stage tumour were identified. All WL–/BL+ lesions and all invasive tumours in the database were used as denominators. Relevant baseline and outcome data were collected. Results: Of the 3514 lesions (1257 unique patients), 818 (23.2%) lesions were WL−/BL+, of those, 55 (7%) lesions were invasive (48 T1, seven T2; 47 unique patients) including 28/55 (51%) de novo invasive lesions (26 unique patients). In all, 21/47 (45%) patients had WL−/BL+ concommitant carcinoma in situ and/or another T1 lesions. Of 22 patients with a WL−/BL+ lesion who underwent radical cystectomy (RC), high-risk pathological features leading to RC was only visible on BLC in 18 (82%) patients. At time of RC, 11/22 (50%) patients had pathological upstaging including four (18%) with node-positive disease. Conclusions: A considerable proportion of invasive lesions are only detectable by BLC and the rate of pathological upstaging is significant. Our present findings suggest an additional benefit of BLC in the detection of invasive bladder tumours that has implications for treatment approach.

KW - bladder cancer

KW - blue-light cystoscopy

KW - cystoscopy

KW - detection rate

KW - diagnosis

KW - invasive tumour

UR - http://www.scopus.com/inward/record.url?scp=85118280389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118280389&partnerID=8YFLogxK

U2 - 10.1111/bju.15614

DO - 10.1111/bju.15614

M3 - Article

C2 - 34637596

AN - SCOPUS:85118280389

SN - 1464-4096

VL - 130

SP - 62

EP - 67

JO - BJU International

JF - BJU International

IS - 1

ER -

Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this